证券代码：603880 证券简称：南卫股份 公告编号：2025-004 江苏南方卫材医药股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2025 年 4 月 29 日在公司会议室举行，本次会议采取现场表决的方式召 开。本次会议通知于 2025 年 4 月 18 日以书面、电话和电子邮件方式通知了全体 监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议的通知、召开及审议 程序符合《公司法》、《证券法》等法律法规及《公司章程》的有关规定，所作决 议合法有效。 二、监事会会议审议情况 1、审议通过《公司 2024 年年度报告及其摘要》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）发布的《江 苏南方卫材医药股份有限公司 2024 年年度报告》及《江苏南方卫材医药股份有 限公司 2024 年年度报告摘要》。 4、审议通过《公司 2024 年度利润 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-003 江苏南方卫材医药股份有限公司 第四届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第四届董事会第十八 次会议于 2025 年 4 月 29 日在公司会议室举行，本次会议采取现场表决与通讯表 决结合的方式召开。本次会议通知于 2025 年 4 月 18 日以书面、电话和电子邮件 方式通知了全体董事。会议应出席董事 7 人，实际出席董事 7 人。本次会议的通 知、召开及审议程序符合《公司法》、《证券法》等法律法规及《公司章程》的有 关规定，所作决议合法有效。 二、董事会会议审议情况 1、审议通过《公司 2024 年年度报告及其摘要》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）发布的《江 苏南方卫材医药股份有限公司 2024 年年度报告》及《江苏南方卫材医药股份有 限公司 2024 年年度报告摘要》。 该议案在提交公司董事会审 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-005 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江苏南方卫材医药股份有限公司（以下简称"公司"）2024 年度的利润分配 预案为：不进行利润分配，也不进行资本公积金转增股本和其他形式的分配。 本次利润分配预案已经公司第四届董事会第十八次会议、第四届监事会第十 五次会议审议通过，尚需提交公司 2024 年年度股东大会审议。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情 形。 一、利润分配预案内容 经天衡会计师事务所（特殊普通合伙）审计，截止 2024 年 12 月 31 日，公司 2024 年度合并报表归属上市公司股东净利润为-190,668,979.26 元，母公司实现净利润 -29,330,281.53 元，根据《公司法》和《公司章程》的有关规定，当年不计提盈余公积， 加 上 年 初 未 分 配 利 润 167,6 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥170,922,078.18, representing a 22.81% increase compared to ¥139,180,514.20 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥7,917,932.55, a decrease of 553.73% from a profit of ¥1,745,086.17 in the previous year[4] - The basic and diluted earnings per share were both -¥0.027, reflecting a decrease of 550.00% from ¥0.006 in the previous year[4] - The company's operating profit for the first quarter of 2025 was -8,022,705.81 RMB, compared to a profit of 992,605.52 RMB in the same period of 2024, indicating a significant decline[17] - Net profit for the first quarter of 2025 was -7,885,264.56 RMB, while in the first quarter of 2024, it was 1,752,439.19 RMB, reflecting a year-over-year decrease[17] - The company reported a total comprehensive income of -7,885,264.56 RMB for the first quarter of 2025, compared to 1,752,439.19 RMB in the same period of 2024, reflecting overall financial challenges[18] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥7,452,517.90, a significant increase of 189.86% compared to a negative cash flow of ¥8,293,570.72 last year[4] - The cash and cash equivalents at the end of the first quarter of 2025 were 19,870,011.98 RMB, compared to 17,393,676.52 RMB at the end of the first quarter of 2024, indicating an increase in liquidity[23] - The company's total cash outflow from investing activities for the first quarter of 2025 was -4,037,316.31 RMB, an improvement from -14,359,402.21 RMB in the same period of 2024, suggesting better investment management[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,038,259,496.21, down 1.73% from ¥1,056,553,004.60 at the end of the previous year[5] - The company's total liabilities decreased to RMB 761,089,984.08 from RMB 772,141,846.66 in the previous period[14] - As of March 31, 2025, total current assets amounted to RMB 392,443,866.70, a slight decrease from RMB 400,280,555.09 as of December 31, 2024[12] Shareholder Equity - Shareholder equity attributable to the company decreased by 2.82% to ¥271,401,379.57 from ¥279,286,644.13 at the end of the previous year[5] - The company had a total of 9,737 common shareholders at the end of the reporting period[8] Revenue and Costs - The total operating costs for Q1 2025 were RMB 182,129,434.69, up from RMB 143,955,213.47 in Q1 2024, reflecting a significant increase in expenses[16] - The increase in operating revenue was primarily due to an overall increase in product sales, although some products experienced price declines due to market competition[7] - The total revenue for the first quarter of 2025 was 168,143,580.99 RMB, an increase from 133,298,618.83 RMB in the first quarter of 2024, representing a growth of approximately 26.1%[20] Investments and Expenses - The long-term equity investments increased to RMB 66,408,440.07 from RMB 63,109,513.51[12] - Research and development expenses for the first quarter of 2025 were 6,177,349.18 RMB, slightly down from 6,652,533.16 RMB in the same period of 2024, indicating a focus on cost management[17] - The company incurred financial expenses of 5,102,755.39 RMB in the first quarter of 2025, a significant increase from 1,318,802.03 RMB in the first quarter of 2024, highlighting rising interest costs[17] Inventory and Receivables - The inventory decreased to RMB 173,339,039.73 from RMB 188,896,130.48, indicating a reduction in stock levels[12] - The company reported a significant increase in accounts receivable, rising to RMB 132,382,068.63 from RMB 104,896,317.55, indicating potential growth in sales but also increased credit risk[12]

Financial Performance - The company's total revenue for 2024 was CNY 602,615,333.02, a slight increase of 0.42% compared to CNY 600,095,343.68 in 2023[24]. - The net profit attributable to shareholders for 2024 was a loss of CNY 190,668,979.26, representing a decline of 29.34% from a loss of CNY 147,417,266.38 in 2023[24]. - The basic earnings per share for 2024 was -CNY 0.66, a decrease of 29.41% from -CNY 0.51 in 2023[25]. - The net profit attributable to shareholders of the parent company was CNY -190.67 million, a decrease of CNY 43.25 million year-on-year[33]. - The company achieved operating revenue of CNY 602.62 million in 2024, an increase of CNY 2.52 million compared to the same period last year[33]. - Operating costs rose to 616.73 million yuan, reflecting a 13.28% increase due to higher sales volume[57]. - The company reported a net profit of -31.82 million RMB for its subsidiary, Southern Meibang, indicating ongoing financial challenges[98]. Cash Flow and Assets - The net cash flow from operating activities increased significantly to CNY 63,320,497.91, up 308.27% from CNY 15,509,532.60 in the previous year[24]. - The company's total assets decreased by 17.28% to CNY 1,056,553,004.60 at the end of 2024, down from CNY 1,277,326,306.30 in 2023[24]. - The net assets attributable to shareholders fell by 40.48% to CNY 279,286,644.13, compared to CNY 469,268,077.30 at the end of 2023[24]. - The company reported a net cash flow from operating activities of CNY 56.82 million in the fourth quarter[28]. Market and Competition - The decline in net profit was attributed to increased market competition, price drops, and rising raw material costs for nitrile gloves[26]. - The company reported that product sales volume increased, but overall revenue was affected by price fluctuations in the industry[26]. - The traditional medical consumables market is expected to exceed CNY 220 billion by 2025, driven by national policies and increasing demand[35]. - The traditional medical supplies market is projected to exceed 220 billion RMB, driven by a 15% annual increase in demand for emergency equipment[37]. - The export value of medical supplies is anticipated to reach 80 billion RMB in 2025, reflecting a 15% year-on-year growth[37]. Research and Development - Research and development expenses amounted to CNY 28.72 million, representing a 1.92% increase from the previous year, focusing on transdermal drug delivery technology and process upgrades[34]. - The company holds 16 invention patents, 73 utility models, and 9 design patents, enhancing its competitive edge in technology development[34]. - The company established a new R&D center in collaboration with Zhejiang University, focusing on transdermal drug delivery technologies[50]. - The company is focusing on R&D, production, and sales of transdermal products, medical adhesive tapes, emergency kits, and protective supplies[38]. Operational Efficiency - The company has effectively reduced operational risks and improved internal control management during the reporting period[33]. - The company is focused on optimizing production management to enhance core competitiveness and reduce costs[34]. - The company employs an "order-based" production model, ensuring production aligns with customer demand[46]. - The company emphasizes technological R&D, continuously upgrading equipment and processes to maintain competitive advantages[49]. Governance and Management - The management team has extensive experience and has established a standardized management system covering all operational aspects[52]. - The company has a diverse board of directors with expertise in law, finance, and management[128]. - The overall management structure supports the company's long-term growth strategy[128]. - The company plans to optimize its governance structure and improve internal control management systems to ensure compliance and efficiency[104]. Shareholder and Investor Relations - The company plans to apply for comprehensive credit facilities from banks and other financial institutions for the year 2024[125]. - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[151]. - The company did not propose any cash profit distribution plan despite having a positive profit available for distribution to shareholders, and it must disclose the reasons and usage plans for undistributed profits[155]. - The company emphasizes investor relations and maintains transparent communication with stakeholders to protect their interests and enhance sustainable development[122]. Environmental and Social Responsibility - The company invested 1.52 million RMB in environmental protection during the reporting period[162]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[164]. - The company adheres to national environmental laws and regulations, actively managing environmental facilities and emissions[166]. - There are no separate disclosures for social responsibility or sustainability reports during the reporting period[168]. Legal and Compliance Issues - The company received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws[182]. - The company has reported a 20% decrease in audit fees compared to the previous year[177]. - The company is involved in significant litigation matters, including disputes with Beijing Sentai Weiye International Trade Co., with a claim amount of 487.10 million RMB[180]. - The company has made provisions for bad debts amounting to 459.31 million RMB related to the litigation with Beijing Sentai Weiye International Trade Co.[180]. Future Outlook and Strategy - The company aims to enhance the profitability of its main products and control production costs and expenses by 2025[102]. - The company is actively pursuing market expansion through the development of new medical products and technologies, aiming to enhance its competitive position in the industry[93]. - The company plans to explore the development of more emergency series products for various fields, including family, traffic accidents, and natural disasters[85]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 100 million allocated for potential deals[130].

江苏南方卫材医药股份有限公司 江苏南方卫材医药股份有限公司 2024 年度营业收入扣除情况表鉴证报告 天衡专字（2025）00585 号 2024 年度营业收入扣除情况表 鉴证报告 【天衡专字（2025）00585 号】 天衡会计师事务所（特殊普通合伙） 江苏南方卫材医药股份有限公司全体股东： 我们接受委托，对江苏南方卫材医药股份有限公司（以下简称"南卫股份"）2024 年 12 月 31 日的合并及母公司资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及财务报表附注进行了审计，并出具了《审计报告》（天衡审 字（2025）01165 号）。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的南卫股份 2024 年度营业收 入扣除情况表（以下简称"营业收入扣除情况表"）执行了合理保证的鉴证业务。 一、管理层的责任 南卫股份管理层的责任是按照《上海证券交易所股票上市规则》和《上海证券交易所上市公 司自律监管指南第 2 号—业务办理》的相关规定编制营业收入扣除情况表，确保营业收入扣除情 况表真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册 ...

关于江苏南方卫材医药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：江苏南方卫材医药股份有限公司 审计单位：天衡会计师事务所（特殊普通合伙） 联系电话：025-84711188 关于江苏南方卫材医药股份有限公司 2024 年度非经营性资金占用及其他关联方 资金往来情况专项说明 【天衡专字（2025）00586 号】 天衡会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zcc.nof.gov.cn） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 关于江苏南方卫材医药股份有限公司 2024 年度非经营性资金占用及其他关联方 资金往来情况专项说明 天衡专字(2025)00586 号 江苏南方卫材医药股份有限公司全体股东: 2025年4月29日 附件: | | 17.14 = | F度非经营性资金占用及其他关联方资金往来情况汇总 | | | | | | | --- | --- | --- | --- | --- | --- | ...

江苏南方卫材医药股份有限公司 2024 年度内部控制审计报告 【天衡专字（2025）00587 号】 天衡会计师事务所(特殊普通合伙) 江苏南方卫材医药股份有限公司 2024 年度内部控制审计报告 天衡专字（2025）00587 号 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是南卫股份董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，南卫股份于2024年12月31日按照《企业内部控制基本规范》和相关规定在 所有重大方面保持了有效的财务报告内部控制。 天衡会计师事务所（特殊普通合伙） 中国注册会计师：罗顺华 江苏南方卫材医药股份有限公司全体股东 ...

Summary of Key Points Core Viewpoint - The article discusses the legal framework for investor compensation under the Securities Law, specifically Article 85, which holds information disclosure obligors accountable for losses incurred by investors due to false statements or omissions in securities-related documents. A total of 124 stocks have been identified for which investors may file claims for compensation [1]. Group 1: Legal Framework and Compensation Conditions - Article 85 of the Securities Law mandates that if information disclosure obligors fail to disclose information as required or if their disclosures contain false statements or significant omissions, they are liable for compensation to investors who suffer losses [1]. - Investors must file claims within a specified statute of limitations; failure to do so will result in the loss of the right to sue, even if they meet the conditions for compensation [1]. Group 2: List of Stocks Eligible for Claims - A total of 124 stocks have been compiled for which investors can pursue claims. Some cases have already seen successful outcomes or substantial progress, with certain investors having received compensation [1]. - The list includes various companies with specific time frames for eligible claims, such as: - Ningke Biological (2022-11-22 to 2023-04-05) - Successful claim [1] - Zhitong Century (2018-04-03 to 2022-11-04) - Successful claim, compensation received [1] - Haiyue Energy (2021-08-31 to 2023-04-28) - Ongoing case [1]. Group 3: Successful Cases and Legal Support - Numerous successful compensation cases have been reported by lawyer Wang Jinlong from Shanghai Zhenya Law Firm, including companies like Annie Co., Baibolong, and Shandong Molong [4]. - Investors are advised to prepare specific documentation for claims, including transaction records and identification documents, which will be handled by the lawyer once the claim conditions are confirmed [5]. Group 4: Legal Representation and Fees - The law firm operates on a risk-based fee model, meaning investors do not need to pay upfront legal fees. Fees are only charged after a successful claim and receipt of compensation [5].